By Dean Seal
Shares of Edgewise Therapeutics advanced after the company reported positive results for its latest trial of sevasemten in patients with Becker muscular dystrophy.
The stock rose 5.4% to $29.11 early in the session. Shares have more than doubled since the start of the year.
The biopharmaceutical company said before the bell that the Phase 2 trial of its sevasemten treatment met its primary endpoint in reducing levels of creatine kinase, a marker of skeletal muscle damage.
Patients treated with sevasemten also showed stabilization in an assessment tied to the trial's secondary endpoint, the company said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 16, 2024 09:38 ET (14:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.